Aandeel 603139 SHAANXI KANGHUI PHARMACEUTICAL CO., LTD.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Shaanxi Kanghui Pharmaceutical Co., Ltd.

Aandelen

603139

CNE100002XT3

slotkoers Shanghai S.E.
Andere beurzen
 00:00:00 30-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
13,94 CNY +0,65% Intraday-grafiek van Shaanxi Kanghui Pharmaceutical Co., Ltd. +10,90% -25,73%
26/04 Shaanxi Kanghui Pharmaceutical Co, Ltd. Rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2024 CI
15/03 Kanghui Pharmaceutical verdient 151 miljoen yuan aan terugkoop Kelavi MT

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Kanghui Pharmaceutical to Earn 151 Million Yuan from Kelavi Buyback
Kanghui Pharma Sanctioned Over Failure to Disclose M&A Deal
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Sichuan Chunsheng Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 56.795265 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
Shaanxi Kanghui Pharmaceutical Co., Ltd. completed the acquisition of an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership).
Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it has received CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.
Shaanxi Kanghui Pharmaceutical Co., Ltd. agreed to acquire an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership) for CNY 30 million.
Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it expects to receive CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers 603139
  4. Nieuws Shaanxi Kanghui Pharmaceutical Co., Ltd.
  5. Andere talen